{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:05:51Z","timestamp":1791137151177,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Patient-Centered Clinical Research Coordinating Center"},{"name":"Ministry of Health & Welfare, Republic of Korea","award":["RS-2021-KH119793"],"award-info":[{"award-number":["RS-2021-KH119793"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Limited data exist on the treatment outcomes of a 2-drug daily regimen of macrolide and ethambutol in patients with Mycobacterium avium complex pulmonary disease (MAC-PD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An outcome analysis was performed on 108 patients with MAC-PD who underwent at least 12 months of treatment with macrolides and ethambutol. Microbiological responses, antibiotic resistance rates, and recurrence rates linked to the regimen were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median overall treatment duration for 108 patients was 13.2 months (interquartile range 12.1\u201314.6 months). A total of 72 (67%) patients achieved culture conversion and microbiological cure, with a median time to culture conversion of 1.7 months (interquartile range 1.2\u20134.0 months). A clinical cure was observed in 11 patients; thus, 83 (77%) patients demonstrated a favorable overall response. In the multivariate analysis models adjusted for important clinical variables, no clinical factors were significantly associated with culture conversion. Among patients who failed to achieve culture conversion, macrolide resistance developed in 2 of 18 patients (11%) who had both pre- and posttreatment isolates available. In 2 other patients who failed culture conversion, the minimum inhibitory concentration for ethambutol in the posttreatment isolates increased to \u22658\u2005\u03bcg\/mL, which was considered resistant. Of the 72 patients who achieved a microbiological cure, 16 (22%) experienced recurrence during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The 2-drug daily regimen of macrolides and ethambutol showed moderate efficacy in treating MAC-PD when used for &amp;gt;12 months. However, macrolide resistance occurred in some refractory cases, and recurrence was noted even after successful treatment, highlighting the need for close follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf292","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T07:41:10Z","timestamp":1747035670000},"source":"Crossref","is-referenced-by-count":6,"title":["Treatment Outcomes of\n                    <i>Mycobacterium avium<\/i>\n                    Complex Pulmonary Disease with a 2-drug Daily Regimen Using Macrolide and Ethambutol"],"prefix":"10.1093","volume":"12","author":[{"given":"Yunjoo","family":"Im","sequence":"first","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University College of Medicine , Seoul ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsu","family":"Choe","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Hun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Young","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6348-8731","authenticated-orcid":false,"given":"Byung Woo","family":"Jhun","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"2025070804164417600_ofaf292-B1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ccm.2023.08.012","article-title":"Global epidemiology of nontuberculous mycobacterial pulmonary disease: a review","volume":"44","author":"Prevots","year":"2023","journal-title":"Clin Chest Med"},{"key":"2025070804164417600_ofaf292-B2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3201\/eid2503.181597","article-title":"Epidemiology of nontuberculous mycobacterial infection, South Korea, 2007\u20132016","volume":"25","author":"Lee","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2025070804164417600_ofaf292-B3","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1183\/09031936.00149212","article-title":"The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study","volume":"42","author":"Hoefsloot","year":"2013","journal-title":"Eur Respir J"},{"key":"2025070804164417600_ofaf292-B4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2025070804164417600_ofaf292-B5","doi-asserted-by":"crossref","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"2025070804164417600_ofaf292-B6","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"key":"2025070804164417600_ofaf292-B7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/cid\/cix517","article-title":"Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis","volume":"65","author":"Kwak","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025070804164417600_ofaf292-B8","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/jac\/dkx311","article-title":"Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease","volume":"72","author":"Pasipanodya","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025070804164417600_ofaf292-B9","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.1093\/cid\/ciaa1361","article-title":"Management of drug toxicity in M. avium complex pulmonary disease\u2014an expert panel survey","volume":"73","author":"van Ingen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025070804164417600_ofaf292-B10","doi-asserted-by":"crossref","first-page":"e0087423","DOI":"10.1128\/aac.00874-23","article-title":"The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease","volume":"67","author":"Schildkraut","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070804164417600_ofaf292-B11","doi-asserted-by":"crossref","first-page":"2302210","DOI":"10.1183\/13993003.02210-2023","article-title":"Rifampicin has no role in treatment of Mycobacterium avium complex pulmonary disease and bactericidal sterilising drugs are needed: a viewpoint","volume":"63","author":"van Ingen","year":"2024","journal-title":"Eur Respir J"},{"key":"2025070804164417600_ofaf292-B12","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1128\/AAC.00770-16","article-title":"Peak plasma concentration of azithromycin and treatment responses in Mycobacterium avium complex lung disease","volume":"60","author":"Jeong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070804164417600_ofaf292-B13","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1378\/chest.15-0543","article-title":"Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and\/or rifampin","volume":"149","author":"Jarand","year":"2016","journal-title":"Chest"},{"key":"2025070804164417600_ofaf292-B14","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2017.04.175","article-title":"Safety and effectiveness of clofazimine for primary and refractory nontuberculous mycobacterial infection","volume":"152","author":"Martiniano","year":"2017","journal-title":"Chest"},{"key":"2025070804164417600_ofaf292-B15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1513\/AnnalsATS.201308-266OC","article-title":"Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study","volume":"11","author":"Miwa","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2025070804164417600_ofaf292-B16","doi-asserted-by":"crossref","first-page":"e01787-19","DOI":"10.1128\/AAC.01787-19","article-title":"Intermittent treatment with azithromycin and ethambutol for noncavitary Mycobacterium avium complex pulmonary disease","volume":"64","author":"Moon","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070804164417600_ofaf292-B17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12890-019-0982-8","article-title":"Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2025070804164417600_ofaf292-B18","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1086\/514748","article-title":"A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex","volume":"28","author":"Gordin","year":"1999","journal-title":"Clin Infect Dis"},{"key":"2025070804164417600_ofaf292-B19","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1164\/rccm.201802-0321OC","article-title":"Development of macrolide resistance and reinfection in refractory Mycobacterium avium complex lung disease","volume":"198","author":"Jhun","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2025070804164417600_ofaf292-B20","doi-asserted-by":"crossref","first-page":"1900798","DOI":"10.1183\/13993003.00798-2019","article-title":"Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study","volume":"55","author":"Jhun","year":"2020","journal-title":"Eur Respir J"},{"key":"2025070804164417600_ofaf292-B21","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.chest.2021.02.025","article-title":"Outcomes of inhaled amikacin-containing multidrug regimens for Mycobacterium abscessus pulmonary disease","volume":"160","author":"Kang","year":"2021","journal-title":"Chest"},{"key":"2025070804164417600_ofaf292-B22","doi-asserted-by":"crossref","first-page":"e01812-17","DOI":"10.1128\/AAC.01812-17","article-title":"Intermittent antibiotic therapy for recurrent nodular bronchiectatic Mycobacterium avium complex lung disease","volume":"62","author":"Jhun","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070804164417600_ofaf292-B23","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.chest.2021.10.048","article-title":"Impact of time between diagnosis and treatment for nontuberculous mycobacterial pulmonary disease on culture conversion and all-cause mortality","volume":"161","author":"Im","year":"2022","journal-title":"Chest"},{"key":"2025070804164417600_ofaf292-B24","doi-asserted-by":"crossref","first-page":"1800170","DOI":"10.1183\/13993003.00170-2018","article-title":"Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement","volume":"51","author":"van Ingen","year":"2018","journal-title":"Eur Respir J"},{"key":"2025070804164417600_ofaf292-B25","doi-asserted-by":"crossref","first-page":"1602503","DOI":"10.1183\/13993003.02503-2016","article-title":"Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype","volume":"50","author":"Koh","year":"2017","journal-title":"Eur Respir J"},{"key":"2025070804164417600_ofaf292-B26","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1164\/rccm.202004-1418OC","article-title":"BACES score for predicting mortality in nontuberculous mycobacterial pulmonary disease","volume":"203","author":"Kim","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2025070804164417600_ofaf292-B27","doi-asserted-by":"crossref","first-page":"7125","DOI":"10.3390\/jcm12227125","article-title":"Spontaneous cultural conversion rate of Mycobacterium avium complex pulmonary disease based on BACES severity","volume":"12","author":"Kim","year":"2023","journal-title":"J Clin Med"},{"key":"2025070804164417600_ofaf292-B28","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41598-022-06022-z","article-title":"Treatment outcomes of Mycobacterium avium complex pulmonary disease according to disease severity","volume":"12","author":"Kim","year":"2022","journal-title":"Sci Rep"},{"key":"2025070804164417600_ofaf292-B29","doi-asserted-by":"crossref","first-page":"e0202721","DOI":"10.1128\/aac.02027-21","article-title":"Relationship between resistance to ethambutol and rifampin and clinical outcomes in Mycobacterium avium complex pulmonary disease","volume":"66","author":"Moon","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070804164417600_ofaf292-B30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0924-8579(01)00461-7","article-title":"Efficacy of macrolides used in combination with ethambutol, with or without other drugs, against Mycobacterium avium within human macrophages","volume":"18","author":"Schiavano","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"2025070804164417600_ofaf292-B31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12890-025-03504-4","article-title":"Tolerability and efficacy of Mycobacterium avium complex pulmonary disease treatment in elderly patients","volume":"25","author":"Shinfuku","year":"2025","journal-title":"BMC Pulm Med"},{"key":"2025070804164417600_ofaf292-B32","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s12931-019-1258-9","article-title":"Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis","volume":"20","author":"Park","year":"2019","journal-title":"Respir Res"},{"key":"2025070804164417600_ofaf292-B33","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/AAC.04577-14","article-title":"Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease","volume":"59","author":"Lee","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf292\/63168349\/ofaf292.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/6\/ofaf292\/63168349\/ofaf292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/6\/ofaf292\/63168349\/ofaf292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T04:16:50Z","timestamp":1751948210000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf292\/8129731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,5,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf292","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,5,13]]},"article-number":"ofaf292"}}